VCYT vs. EXAS

Last updated Jun 3, 2026

VCYT (Veracyte, Inc.) and EXAS (Exact Sciences Corporation) are both stocks. Both are in the Healthcare sector — VCYT in Biotechnology, EXAS in Diagnostics & Research. At a 0.41 correlation, their price movements are largely independent.

Performance

VCYT vs. EXAS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Veracyte, Inc. (VCYT) and Exact Sciences Corporation (EXAS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

VCYT

• 1D: -0.79%
• 1M: 44.45%
• YTD: 13.54%
• 6M: 3.55%
• 1Y: 78.76%
• 3Y*: 21.39%
• 5Y*: 7.11%
• 10Y*: 24.60%

EXAS

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

VCYT vs. EXAS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
VCYT Veracyte, Inc.	13.54%	6.31%	43.95%	15.93%	-42.40%	-15.82%	75.29%	121.94%	92.65%	-15.63%
EXAS Exact Sciences Corporation	3.30%	80.74%	-24.05%	49.42%	-36.39%	-41.26%	43.26%	46.56%	20.10%	293.26%

Correlation

The correlation between VCYT and EXAS is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.24
Correlation (3Y) Calculated over the trailing 3-year period	0.40
Correlation (5Y) Calculated over the trailing 5-year period	0.56
Correlation (10Y) Calculated over the trailing 10-year period	0.45
Correlation (All Time) Calculated using the full available price history since Oct 31, 2013	0.41

The correlation between VCYT and EXAS shifts across timeframes, from 0.24 (1 year) to 0.56 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap VCYT : $3.89B EXAS : $19.91B
EPS VCYT : $1.09 EXAS : -$1.10
PS Ratio VCYT : 7.11 EXAS : 6.12
PB Ratio VCYT : 2.89 EXAS : 8.29
Total Revenue (TTM) VCYT : $541.74M EXAS : $3.25B
Gross Profit (TTM) VCYT : $386.89M EXAS : $2.26B
EBITDA (TTM) VCYT : $99.47M EXAS : $42.61M

Return for Risk

VCYT vs. EXAS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VCYT

VCYT Risk / Return Rank: 77
VCYT Sharpe Ratio Rank: 77
VCYT Sortino Ratio Rank: 82
VCYT Omega Ratio Rank: 77
VCYT Calmar Ratio Rank: 74
VCYT Martin Ratio Rank: 72

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VCYT vs. EXAS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Veracyte, Inc. (VCYT) and Exact Sciences Corporation (EXAS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VCYT	EXAS	Difference
Sharpe ratio Return per unit of total volatility	1.32	—	—
Sortino ratio Return per unit of downside risk	2.53	—	—
Omega ratio Gain probability vs. loss probability	1.29	—	—
Calmar ratio Return relative to maximum drawdown	2.03	—	—
Martin ratio Return relative to average drawdown	4.42	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	VCYT	EXAS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.32	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.11	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.40	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.18	—	—

Drawdowns

Drawdown Indicators

	VCYT	EXAS	Difference
Max Drawdown Largest peak-to-trough decline	-81.19%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-39.23%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-50.09%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-71.54%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-81.19%	—	—
Current Drawdown Current decline from peak	-41.26%	—	—
Average Drawdown Average peak-to-trough decline	-48.36%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	18.02%	—	—

Volatility

Volatility by Period

	VCYT	EXAS	Difference
Volatility (1M) Calculated over the trailing 1-month period	26.45%	—	—
Volatility (6M) Calculated over the trailing 6-month period	39.28%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	59.88%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	64.48%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	62.00%	—	—

Dividends

VCYT vs. EXAS - Dividend Comparison

Neither VCYT nor EXAS has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

VCYT vs. EXAS - Profitability Comparison

The chart below illustrates the profitability comparison between Veracyte, Inc. and Exact Sciences Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

VCYT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Veracyte, Inc. reported a gross profit of 101.16M and revenue of 139.07M. Therefore, the gross margin over that period was 72.7%.

EXAS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported a gross profit of 615.83M and revenue of 878.38M. Therefore, the gross margin over that period was 70.1%.

VCYT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Veracyte, Inc. reported an operating income of 22.65M and revenue of 139.07M, resulting in an operating margin of 16.3%.

EXAS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported an operating income of -76.68M and revenue of 878.38M, resulting in an operating margin of -8.7%.

VCYT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Veracyte, Inc. reported a net income of 28.71M and revenue of 139.07M, resulting in a net margin of 20.6%.

EXAS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported a net income of -85.96M and revenue of 878.38M, resulting in a net margin of -9.8%.

Frequently Asked Questions

Can I hold both VCYT and EXAS in my portfolio?

VCYT and EXAS have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.